NZ504420A - Combination of tetrahydropyridins and acetylcholinesterase inhibiting agents, for treating senile dementia such as alzheimer dementia - Google Patents

Combination of tetrahydropyridins and acetylcholinesterase inhibiting agents, for treating senile dementia such as alzheimer dementia

Info

Publication number
NZ504420A
NZ504420A NZ504420A NZ50442098A NZ504420A NZ 504420 A NZ504420 A NZ 504420A NZ 504420 A NZ504420 A NZ 504420A NZ 50442098 A NZ50442098 A NZ 50442098A NZ 504420 A NZ504420 A NZ 504420A
Authority
NZ
New Zealand
Prior art keywords
tetrahydropyridine
ethyl
trifluoromethylphenyl
biphenylyl
alkyl
Prior art date
Application number
NZ504420A
Other languages
English (en)
Inventor
Jean-Pierre Maffrand
Philippe Soubrie
Jean-Paul Terranova
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9714324A external-priority patent/FR2771006B1/fr
Priority claimed from FR9714322A external-priority patent/FR2771007B1/fr
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of NZ504420A publication Critical patent/NZ504420A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ504420A 1997-11-14 1998-11-09 Combination of tetrahydropyridins and acetylcholinesterase inhibiting agents, for treating senile dementia such as alzheimer dementia NZ504420A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9714324A FR2771006B1 (fr) 1997-11-14 1997-11-14 Association de principes actifs pour le traitement de la demence senile du type alzheimer
FR9714322A FR2771007B1 (fr) 1997-11-14 1997-11-14 Association de principes actifs pour le traitement de la demence senile du type alzheimer
PCT/FR1998/002384 WO1999025363A1 (fr) 1997-11-14 1998-11-09 Association de principes actifs, notamment de tetrahydropyridines et d'agents inhibiteurs de l'acetylcholinesterase, pour le traitement de la demence senile du type alzheimer

Publications (1)

Publication Number Publication Date
NZ504420A true NZ504420A (en) 2003-08-29

Family

ID=26233932

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ504420A NZ504420A (en) 1997-11-14 1998-11-09 Combination of tetrahydropyridins and acetylcholinesterase inhibiting agents, for treating senile dementia such as alzheimer dementia

Country Status (27)

Country Link
EP (1) EP1030671A1 (fr)
JP (1) JP2001523642A (fr)
KR (1) KR100599350B1 (fr)
CN (1) CN1243540C (fr)
AU (1) AU743228B2 (fr)
BG (1) BG64819B1 (fr)
BR (1) BR9814035A (fr)
CA (1) CA2309966A1 (fr)
CO (1) CO4980891A1 (fr)
DZ (1) DZ2649A1 (fr)
EA (1) EA003255B1 (fr)
EE (1) EE04235B1 (fr)
HU (1) HUP0100098A3 (fr)
ID (1) ID24933A (fr)
IL (2) IL136122A0 (fr)
IS (1) IS5482A (fr)
MY (1) MY120461A (fr)
NO (1) NO20002450L (fr)
NZ (1) NZ504420A (fr)
OA (1) OA11464A (fr)
PL (1) PL194597B1 (fr)
SA (1) SA98190747B1 (fr)
SK (1) SK286040B6 (fr)
TR (1) TR200001262T2 (fr)
TW (1) TW585766B (fr)
UY (1) UY25247A1 (fr)
WO (1) WO1999025363A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481565B2 (en) 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE041842T2 (hu) 2002-06-14 2019-05-28 Toyama Chemical Co Ltd Gyógyászati készítmény agymûködés javítására
JP2005534710A (ja) * 2002-08-07 2005-11-17 ノバルティス アクチエンゲゼルシャフト Ａｐｏｅ遺伝子型を基準とした痴呆を処置するための方法
CN1520818A (zh) * 2003-02-09 2004-08-18 ɽ����Ҷ��Ȼҩ���о��������޹�˾ 治疗老年性痴呆的胆碱酯酶抑制剂药物组合物
RU2692258C2 (ru) 2014-01-31 2019-06-24 Когнишн Терапьютикс, Инк. Композиции изоиндолина и способы лечения нейродегенеративного заболевания
DK3634394T3 (da) 2017-05-15 2026-03-02 Cognition Therapeutics Inc Sammensætninger til behandling af neurogenerative sygdomme
KR102224918B1 (ko) 2018-03-20 2021-03-09 (주)인벤티지랩 도네페질 및 메만틴을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 복합 조성물 및 이의 제조 방법
WO2019182319A1 (fr) * 2018-03-20 2019-09-26 (주)인벤티지랩 Procédé de préparation de composition pharmaceutique de prévention ou de traitement de maladies associées au trouble cognitif, et composition pharmaceutique de prévention ou de traitement de maladies associées au trouble cognitif, préparée par le procédé de préparation
CN109265391B (zh) * 2018-11-13 2021-11-19 枣庄学院 联苯多取代1,2,5,6-四氢吡啶化合物及其合成方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
US5453428A (en) * 1991-02-14 1995-09-26 The Mount Sinai School Of Medicine Of The City Of New York Method and composition for the treatment of apathy-amotivation syndrome
ES2244968T3 (es) * 1995-03-06 2005-12-16 Interneuron Pharmaceuticals Incorporated Reduccion del volumen de infarto usando citocolina.
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481565B2 (en) 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US8507527B2 (en) 2004-12-27 2013-08-13 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug

Also Published As

Publication number Publication date
CN1285742A (zh) 2001-02-28
EP1030671A1 (fr) 2000-08-30
DZ2649A1 (fr) 2004-12-28
BR9814035A (pt) 2000-09-26
TW585766B (en) 2004-05-01
CA2309966A1 (fr) 1999-05-27
BG64819B1 (bg) 2006-05-31
UY25247A1 (es) 2001-05-31
EE200000290A (et) 2001-06-15
AU1160999A (en) 1999-06-07
KR100599350B1 (ko) 2006-07-12
OA11464A (en) 2003-11-18
CO4980891A1 (es) 2000-11-27
PL194597B1 (pl) 2007-06-29
SK286040B6 (sk) 2008-01-07
IL136122A (en) 2006-07-05
EA200000412A1 (ru) 2000-12-25
KR20010032099A (ko) 2001-04-16
NO20002450D0 (no) 2000-05-11
JP2001523642A (ja) 2001-11-27
EA003255B1 (ru) 2003-02-27
SA98190747B1 (ar) 2006-11-04
CN1243540C (zh) 2006-03-01
BG104428A (en) 2001-08-31
TR200001262T2 (tr) 2001-01-22
IS5482A (is) 2000-05-09
SK7112000A3 (en) 2000-10-09
EE04235B1 (et) 2004-02-16
HUP0100098A2 (hu) 2001-07-30
MY120461A (en) 2005-10-31
IL136122A0 (en) 2001-05-20
NO20002450L (no) 2000-07-14
PL340500A1 (en) 2001-02-12
WO1999025363A1 (fr) 1999-05-27
ID24933A (id) 2000-08-31
HUP0100098A3 (en) 2001-12-28
AU743228B2 (en) 2002-01-24

Similar Documents

Publication Publication Date Title
EP0216555B1 (fr) Utilisation de dérivés de la dioxopipéridine pour le traitement de l'anxiété, pour la réduction des niveaux de la sérotonine ou de l'acide 5-hydroxy-indoleacétique chroniquement anormalement élevés dans le cerveau, et pour le traitement des infections bact
Settle Jr Bupropion sustained release: side effect profile
MXPA02011610A (es) Combinacion de sustancia activa que contiene un opioide que tiene una estructura tipo fentanilo y cetamina.
CA2323618A1 (fr) Combinaison d'un agoniste inverse alpha 5 gaba-a et inhibiteur d'acetylcholinesterase
AU2004283425A1 (en) Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
NZ504420A (en) Combination of tetrahydropyridins and acetylcholinesterase inhibiting agents, for treating senile dementia such as alzheimer dementia
US20030092737A1 (en) Combination of active ingredients for the treatment of senile dementia of the Alzheimer type
WO2004091615A1 (fr) Combinaisons de paroxetine et de 2-(r)-(4-fluoro-2-methyl-phenyl)-4-(s)-((8as)-6-oxo-hexahydro-pyrrolo[1,2-a]-pyrazin-2-yl)-piperidine-1-acide carboxylique[1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide utilisees dans le traitement de la depression et/ou de l'anxiete
US4017614A (en) Compositions for the relief of migraine
MXPA00004600A (en) Combination of active principles, in particular of tetrahydropyridins and acetylcholinesterase inhibiting agents, for treating senile dementia such as alzheimer dementia
CN102711746A (zh) 用于治疗酒精依赖的药物组合物
WO1998034615A1 (fr) Composition pharmaceutique contenant de l'oxime, pour le traitement de dysfonctionnement synaptique
CZ20001734A3 (cs) Farmaceutická kompozice a její použití
CA2188227C (fr) Therapie antiemetique combinatoire utilisant des antagonistes des recepteurs nk-1
JPWO2001022997A1 (ja) 鎮痛薬
SI21062A2 (sl) Farmacevtski sestavki, ki obsegajo amlodipin maleat

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)